Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree 100%
$3 for now, by 2013 they are predicting this to be a 275 billion dollar industry, I n holding this one long!! And will see $20PPS then.
Thanks Ron, good to be here, I cant send private msg, but I sold out AMRN at $17.50, I will check out the notes..
I still like AMRN think it will get to $30 by EOY, waiting to re-enter though.
Im all in here just like I was AMRN at $4..Haa
I'm on board 20k shares, ready to roll!
LOL, really...Great day good to see it close close to HOD..
It could be close to 40 billion dollar market..
Worst case scenario with just AMR101, it is being valued at $12
I agree 100%
Great to see goldman sacchs covering AMRN with a $12 target. based solely on AMR101, Not Including Anchor results which is maybe 20x the market size..
Historical Trial Data Bodes Well for Amarin
http://seekingalpha.com/article/259810-historical-trial-data-bodes-well-for-amarin?source=yahoo
Yeah they sold 144k shares, now they're just holding just over 7 million.
I'm not sure, could be many of things..
Lazard already covers AMRN.. Should be interesting though..
theflyonthewall.com: Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on March 24 hosted by Lazard Capital
I've never got burned.. This is no weight loss drug
Im saying from my experience , not saying to buy or sell..
You need to know. And from my DD its a buy, I will risk my 100k.
wait for results and see we're we are at
there just under 10% ownership now holding just under 10 million shares..
Fear is only created if you dont do your DD, and dont know what your investing in, I have, and thats why I hold one stock and that is AMRN..
This will have alot more benefits, thats what they are saying..
Thats excatly whats hgappening, shares are going from one instituition to another, and thos who are selling are going just under 10% ownership, they still hols 10 million shares after taking somne profits of probably over 500%.. I would do the same.
This will be a homerun, there is no downside IMO..
Just look at the Marine results..many newbies dont really know what this drug is about, it has a HUGE market and there are no side effects..
whats really impressive is most were June 15 calls..
Looks like it was a planned sale at $7.50 between two parties.
1000k shares were traded, means absolutlety nothing its to scare newbie investors who dont know any better, if volume was over 100k then I would would be worried.
Had to be good, volume on the June 15 calls were Unreal!
Going under 7$7 took out stop losses and the weak hands which is a good thing..
I seen this way too many times myself, If I was new to the game I would have proabaly of sold too being down $20k over the last month..
I see it getting to $10 over the next few weeks..
LOL, he has been a good boy..
Sure is one of my favorites, get used to seeing it alot these next couple of weeks..
No Whining today...Lovely...:)
That was most likely a pre-arranged sell between two parties.
This should clear the way, for the ride back up to $9's..
June 15 Options are getting gobbled up today.. Volume is insane, I see the conference got clients to spend over $4 million on these calls..
Leerink's biotech analyst holds an analyst/industry conference call
Biotech Analyst Schwartz discusses prospects for Amarin's AMR-101 in the treatment of mixed Dyslipidemia: previewing the ANCHOR Study on an Analyst/Industry conference call being held on March 10 at 11 am hosted by Leerink.
www.theflyonthewall.com/.../AMRNid1391681/AMRN-Leerinks-biotech-analyst-holds-an-analystindustry-conference-call
cant reply in private, but i hear ya
I was never confident in PLX
The last time i went all in was with LVS at $2.25
Im pretty confident here, as i have done tons of DD, and believe things will work out
Even if Anchor is not as good as it should be
Amr101 is a billion dollar drug, PPS should be $11 to $13 just for that..
I believe a buyout or partnership will come soon...Im not advising anyone to folow me, but its a gamblw in which i feel the odds are gretaly with me.,
GLTU!! as all AMRN longs will get rewarded, it's touhg seeing losses as i have seen my account go down 20K in this drop, but i am very confident..
you got that right, and thats why im 100% invested in AMRN
AMR101 is at minimum a billion dollar drug a year
Anchor results are good, it will be MULTIbillion,
Thats a good enough pipleline for me
and seems to be for the institutions who hold over 66 million shares..
You can listen to webcast here
Those who hold this long will be very happy..
http://investor.amarincorp.com/events.cfm
Yes Time Schedule
Amarin to Present at Two Upcoming Investor Conferences
MYSTIC, Conn. and DUBLIN, Feb 22, 2011 Amarin Corporation plc (Nasdaq: AMRN) today announced that members of its senior management team will be presenting at two investor conferences on March 2, 2011.
Joseph Zakrzewski, Executive Chairman and Chief Executive Officer, is scheduled to present at the CITI 2011 Global Healthcare Conference on Wednesday, March 2, 2011 at 2:00 pm ET. This conference will be held at the Hilton New York City. A live audio webcast of the presentation will be available at http://www.veracast.com/webcasts/citigroup/healthcare2011/75211419.cfm.
John Thero, President, is scheduled to present at the RBC Capital Markets' Healthcare Conference on Wednesday, March 2, 2011 at 4:35 pm ET. This conference will be held at the New York Palace Hotel in New York City. A live audio webcast of the presentation will be available at http://www.wsw.com/webcast/rbc129/amrn.
About Amarin
Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl, formerly called ethyl icosapentate). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (=200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.
Investor Contact Information:
Stephen Schultz
Investor Relations and Corporate Communications
Amarin Corporation
In U.S.: +1 (860) 572-4979
investor.relations@amarincorp.com
Lee M. Stern
The Trout Group
In U.S.: +1 (646) 378-2922
lstern@troutgroup.com
Doesn't mean anything since the sales were prearranged before either company officer would have knowledge of such an event. That is the purpose of the 10b5-1 sales plan... to keep insiders from trading on non public business/company information.
They were about 10k shares traded after hours yesterday, I personally hold more shares, so its not HUGE..lol
Here is a good article, most analysts have a conservative $12PPS target just basing on AMR101
Amerin Poised for Takeover on Strength of Drug Study Results
Amarin Corp. (AMRN) has certainly been a great stock to own ever since our call back in late October, when the stock was trading around $3; gaining over 300% since then. Recent comments from the CEO suggest that they are on multiple shopping lists out of big pharma. Lately, it has gotten a lot of attention from the investment community following a capital raise where banks and institutions were buying shares by the millions. They raised roughly $100 million dollars and the market completely absorbed it; they even maxed out the over-allotment on the offering. That’s a powerful buy signal for retail investors to take notice. Bloomberg's recent story on Amarin is a must read for investors. While at the J.P. Morgan Healthcare Conference, Bloomberg interviewed CEO Joe Zakrzewski, who had this to say, “I have more companies interested in this asset than employees.” The company employs 17 people, he said. ” When we first saw the original MARINE data back at the end of November, we figured there would certainly be interest in AMR-101, but we could have never imagined that big pharmas would be flooding Amarin with offers. There is so much interest, that Amarin will be retaining a financial adviser to review the alternatives and offers, since they have received interest from over a dozen companies.
To briefly review, AMR101(ethyl icosapentate) is a purified, prescription-grade omega-3 fatty acid compound that is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels (MARINE) and the other for the treatment of patients with high triglycerides with mixed dyslipidemia (ANCHOR). The MARINE study’s objective were to determine the efficacy of AMR101 versus placebo in lowering triglyceride levels in patients with very high triglyceride levels (500 = TGL = 2000 mg/dL). While the ANCHOR study (most important) is aimed at those with high triglyceride levels(200 = TGL = 500 mg/dL). Both Phase 3 trials are being conducted under Special Protocol Assessment agreements with the FDA.
Amarin delivered results from the MARINE study back in November, which showed that AMR-101 was able to demonstrate a significant reduction in triglyceride levels without effecting .The patient group treated with 4 grams of AMR101 showed a significant median TG decrease of 33 % (P 750 mg/dL(39% of all patients), the effect of AMR101 in reducing TG levels was even more prominent. In this group, the median decrease in TG levels from placebo was 45% for 4 grams and 33% for 2 grams, both statistically significant (P= 0.0001 for 4 grams and P= 0.0016 for 2 grams, respectively). Additionally, those on background statin therapy had much greater median reductions in TG, which were also statistically significant, than those not on statin therapy. They expect to release more details about the study at an upcoming scientific meeting in April.
As we stressed earlier, AMR-101 continues to outshine Lovaza by demonstrating a better cholesterol profile. AMR-101 did not increase levels of low-density lipoprotein (LDL-C), or "bad cholesterol", in this study. This is a significant side effect for those taking Lovaza, as it can require additional treatment with statins. This was the first triglyceride-lowering therapy studied to demonstrate a lack of elevation in LDL-C. There was also a statistically significant decrease in median non-HDL-C (total cholesterol less "good cholesterol") compared to placebo with both of the AMR101 treated groups (-18% for the 4 gram group [p < 0.001] and -8% for the 2 gram group [p < 0.05]). Additionally, Amarin saw significant reductions in several important lipid markers, including Apo B, Lp-PLA2 (Lipoprotein-phospholipase A2), VLDL-C and total cholesterol. Lovaza can raise LDL-C by 45%, whereas AMR-101 does not. AMR-101 will offer primary-care physicians a much better option for lowering triglycerides without raising bad cholesterol.
Yesterday morning, they were spotlighted on CNBC by Hapoalim Securities’ analyst, Jon LeCroy, who gave a bullish investment thesis for buying Amarin. LeCroy thinks AMR101, Amarin’s lead product, could have peak annual sales of $1 billion and values a potential acquisition of them at around $4 billion. By the way, they have Amarin rated as a ‘Buy’ with a $12 price target. In our view, Lecroy’s estimates are failry conservative, since they are most likely factoring in the risk associated with pending results from the ANCHOR study.
If the ANCHOR study results are successful, AMR101 has the potential to address a substantially larger patient population than Lovaza. Lovaza is currently labeled to help patients with triglyceride levels greater than 500 mg/dL, whereas AMR101 could potentially be used for those with triglycerides from 200 to 2000 mg/dL, which would be the broadest label for this indication. AMR101 has the potential to address over 100 million patients in the United States if approved and both studies show strong efficacy. AMR101 also does not have the fishy taste, smell or belching, and skin reactions that are common for Lovaza.( Lovaza had global sales of over $1 billion in 2009.) With positive results in the ANCHOR study, Amarin has the all the makings of a multi-billion dollar takeover in 2011
http://seekingalpha.com/article/247090-amerin-poised-for-takeover-on-strength-of-drug-study-results?source=yahoo
Instituitional Ownership
Huge Jump!!
Previous Shares Held By Institutions 29,234,651 Net Shares Changed (Pct): 33,703,244 (115.28%)
Current Shares Held By Institutions 62,937,895
Amarin may get bought out by GSK
http://online.wsj.com/public/resources/documents/dealpredictions951.pdf
JEFFRIES initiates buy with a target of $12
http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Amarin+Corporation+(AMRN)+at+Buy/6252218.html
News From Bloomberg Tv
http://www.bloomberg.com/news/2011-01-10/amarin-ceo-seeks-financial-adviser-after-interest-from-buyers-partners.html
Amarin CEO Seeks Financial Adviser After Interest From Buyers, Partners
By Sasha Damouni - Jan 10, 2011 7:22 PM ET
inShare.0More
Business ExchangeBuzz up!DiggPrint Email .Amarin Corp. Plc, a cholesterol drug developer with no approved products, will retain a financial adviser to review its alternatives and has fielded calls from more than a dozen interested parties, Chief Executive Officer Joe Zakrzewski said today in an interview.
Zakrzewski said he has had interest from potential partners and buyers. “I have more companies interested in this asset than employees,” he said today at the J.P. Morgan Healthcare Conference in San Francisco. The company employs 17 people, he said.
Amarin, based in London, has two final-stage human tests of its most advanced experimental drug, AMR101 for high cholesterol. Zakrzewski said the company plans to present phase three results from one of the studies, called Marine, in April at the American College of Cardiology meeting. Results from the second trial, called Anchor, may be reported in the second quarter of 2011, he said.
“Amarin will rapidly become an acquisition candidate following the results of Anchor, which could lead to a buyout in 2011,” said Duane Nash, an analyst with Wedbush Securities in San Francisco, in a Dec. 29 research report.
Amarin’s drug may lure buyers because it has minimal risk of rejection by regulators and there is “a growing need for large pharmaceutical companies to augment their cardiovascular drug portfolios.”
Fish Oils
AMR101 is an omega-3 fatty acid sourced from certain fish oils and would compete with GlaxoSmithKline Plc’s Lovaza, the only similar prescription drug approved in the U.S. Lovaza generated sales of 450 million pounds ($703 million) for the U.K company in 2009. Amarin said on Nov. 29 it would seek U.S. approval of its drug this year.
Zakrzewski said his drug may be safer than Lovaza, and less likely to cause burping or skin irritations linked to Glaxo’s product.
To contact the reporter on this story: Sasha Damouni in New York at sdamouni2@bloomberg.net
To contact the editor responsible for this story: Reg Gale at Rgale5@bloomberg.net
.